The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 637-641

  Saeki, Harumi ^a   Hashizume, Akane ^a   Izumi, Hiroshi ^a   Suzuki, Fujihiko ^a   Ishi, Kazuhisa ^a   Nojima, Michio ^a   Maeda, Masahiro ^b   Okio, Hino ^c  

^a JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Biomarker; ELISA; Mesothelin; Ovarian carcinoma; Serous adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; MESOTHELIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; EARLY DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PATIENT MONITORING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE SECTION;

EID: 84864685883     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.796     Document Type: Article

References (11)

1. Shiomi K, Miyamoto H, Segawa T, et al: Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97: 928-932, 2006.
2. Shiomi K, Hagiwara Y, Sonoue K, et al: Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 14: 1431-1437, 2008.
3. Imashimizu K, Shiomi K, Maeda M, et al: Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma. Exp Ther Med2: 409-411, 2011.
4. Ho M, Hassan R, Zhang J, Wang Q, Onda M, Bera T and PastanI: Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 11: 3814-3820, 2005.
5. Hino O, Kobayashi E, Nishizawa M, et al: Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 121: 602-605, 1995.
6. Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942, 2004.
7. Hassan R, Remaley AT, Sampson ML, et al: Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12: 447-453, 2006.
8. Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M and HinoO: Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. Pathol Int 59: 161-166, 2009.
9. Kurman RJ and Shin IM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443, 2010.
10. Scully RE and Barlow JF: "Mesonephroma" of ovary. Tumor of Müllerian nature related to the endometrioid carcinoma. Cancer 20: 1405-1417, 1967.
11. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y and Hellstrom KE: Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarker Prev15: 1014-1020, 2006.